tbuckley/cabot-search huggingface dataset:
Association Between Prison Crowding and COVID-19 Incidence Rates in Massachusetts Prisons, April 2020-January 2021
Authors: Abigail I. Leibowitz, Mark J. Siedner, Alexander C. Tsai, Amir M. Mohareb
Journal: JAMA Internal Medicine (2021)

COVID-19 incidence and mortality are higher among incarcerated persons than in the general US population, but the extent to which prison crowding contributes to their COVID-19 risk is unknown.To estimate the associations between prison crowding, community COVID-19 transmission, and prison incidence rates of COVID-19.This was a longitudinal ecological study among all incarcerated persons in 14 Massachusetts state prisons between April 21, 2020, and January 11, 2021.The primary exposure of interest was prison crowding, measured by (1) the size of the incarcerated population as a percentage of the prison's design capacity and (2) the percentage of incarcerated persons housed in single-cell units. The analysis included the weekly COVID-19 incidence in the county where each prison is located as a covariate.The primary outcome was the weekly COVID-19 incidence rate as determined by positive SARS-CoV-2 tests among incarcerated persons at each prison over discrete 1-week increments.There was on average 6876 people incarcerated in 14 prisons during the study period. The median level of crowding during the observation period ranged from 25% to 155% of design capacity. COVID-19 incidence was significantly higher in prisons where the incarcerated population was a larger percentage of the prison's design capacity (incidence rate ratio [IRR] per 10-percentage-point difference, 1.14; 95% CI, 1.03-1.27). COVID-19 incidence was lower in prisons where a higher proportion of incarcerated people were housed in single-cell units (IRR for each 10-percentage-point increase in single-cell units, 0.82; 95% CI, 0.73-0.93). COVID-19 transmission in the surrounding county was consistently associated with COVID-19 incidence in prisons (IRR [for each increase of 10 cases per 100 000 person-weeks in the community], 1.06; 95% CI, 1.05-1.08).This longitudinal ecological study found that within 14 Massachusetts state prisons, increased crowding was associated with increased incidence rates of COVID-19. Researchers and policy makers should explore strategies that reduce prison crowding, such as decarceration, as potential ways to mitigate COVID-19 morbidity and mortality among incarcerated persons.
Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review
Authors: Jinshou Yang, Ruiyuan Xu, Chengcheng Wang, Jiangdong Qiu, Bo Ren, Lei You
Journal: Cancer Communications (2021)

Abstract Pancreatic cancer is a highly malignant digestive system tumor with a poor prognosis. Most pancreatic cancer patients are diagnosed at an advanced stage or even metastasis due to its highly aggressive characteristics and lack of typical early symptoms. Thus, an early diagnosis of pancreatic cancer is crucial for improving its prognosis. Currently, screening is often applied in high‐risk individuals to achieve the early diagnosis of pancreatic cancer. Fully understanding the risk factors of pancreatic cancer and pathogenesis could help us identify the high‐risk population and achieve early diagnosis and timely treatment of pancreatic cancer. Notably, accumulating studies have been undertaken to improve the detection rate of different imaging methods and the diagnostic accuracy of endoscopic ultrasound‐guided fine‐needle aspiration (EUS‐FNA) which is the golden standard for pancreatic cancer diagnosis. In addition, there are currently no biomarkers with sufficient sensitivity and specificity for the diagnosis of pancreatic cancer to be applied in the clinic. As the only serum biomarker approved by the United States Food and Drug Administration, carbohydrate antigen 19‐9 (CA19‐9) is not recommended to be used in the early screening of pancreatic cancer because of its limited specificity. Recently, increasing numbers of studies focused on the discovering of novel serum biomarkers and exploring their combination with CA19‐9 in the detection of pancreatic cancer. Besides, the application of liquid biopsy involving circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), microRNAs (miRNAs), and exosomes in blood and biomarkers in urine, and saliva in pancreatic cancer diagnosis are drawing more and more attention. Furthermore, many innovative technologies such as artificial intelligence, computer‐aided diagnosis system, metabolomics technology, ion mobility spectrometry (IMS) associated technologies, and novel nanomaterials have been tested for the early diagnosis of pancreatic cancer and have shown promising prospects. Hence, this review aims to summarize the recent progress in the development of early screening and diagnostic methods, including imaging, pathological examination, serological examination, liquid biopsy, as well as other potential diagnostic strategies for pancreatic cancer.
Aberrant NAD+ metabolism underlies Zika virus–induced microcephaly
Authors: Huanhuan Pang, Yisheng Jiang, Jie Li, Yushen Wang, Meng Nie, Nan Xiao, Shuo Wang, Zhihong Song, Fansen Ji, Yafei Chang, Yu Zheng, Ke Yao, LiAng Yao, Shao Li, Peng Li, Lei Song, Xun Lan, Zhiheng Xu, Zeping Hu
Journal: Nature Metabolism (2021)
Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer
Authors: Jake S. Jacob, Barbara E. Dutra, Victor Garcia-Rodriguez, Kavea Panneerselvam, Fiyinfoluwa O. Abraham, Fangwen Zou, Weijie Ma, Petros Grivas, John A. Thompson, Mehmet Altan, Isabella C. Glitza Oliva, Hao Chi Zhang, Anusha S. Thomas, Yinghong Wang
Journal: Journal of the National Comprehensive Cancer Network (2021)

Immune checkpoint inhibitor (ICI) therapy predisposes patients to immune-related adverse events (irAEs). Data are limited regarding the incidence, management, and outcomes of one such irAE: mucositis. In this study, we evaluated the clinical characteristics, disease course, treatment, and outcomes of ICI-mediated mucositis.This was a retrospective, single-center study of patients who received ICI therapy and developed oral mucositis at The University of Texas MD Anderson Cancer Center from January 2009 to September 2019. Inclusion criteria included age ≥18 years, a diagnosis of oral mucositis and/or stomatitis based on ICD-9 and ICD-10 codes, and therapy using CTLA-4 or PD-1/L1 inhibitors alone or combined with other agents.We identified 152 patients with a mean age of 60 years, 51% of whom were men. Of the sample patients, 73% had stage IV cancer, with melanoma the most common (28%). Median time from ICI initiation to mucositis was 91 days. The most common clinical presentation of mucositis was odynophagia and/or oral pain (89%), 91% developed CTCAE grade 1-2 mucositis, and 78% received anti-PD-1/L1 monotherapy. Compared with anti-PD-1/L1-based therapy, anti-CTLA-4-based therapy was more frequently associated with earlier onset of mucositis (73 vs 96 days; P=.077) and a lower rate of symptom resolution (76% vs 92%; P=.029); 24% of patients required immunosuppressive therapy, which was associated with longer symptom duration (84 vs 34 days; P=.002) and higher mucositis recurrence rate (61% vs 32%; P=.006). ICI interruption was associated with worse survival (P=.037). Mucositis recurrence, immunosuppressant use, and presence of other irAEs did not affect survival.For ICI-mediated mucositis, a diagnosis of exclusion has not been well recognized and is understudied. Although the clinical symptoms of mucositis are mostly mild, approximately 25% of patients require immunosuppression. Mucositis recurrence can occur in approximately 39% patients. Our results showed that ICI interruption compromises overall survival.
Endothelial CFTR dysfunction and its involvement in the pathogenesis of pulmonary arterial hypertension
Authors: Mathias Declercq, Lucas Treps, Siham Bousfia, Peter Carmeliet, Peter Witters
Journal: European Respiratory Journal (2021)

F. Antigny and co-workers raise interesting points in their comment on the transcriptomic analysis of cystic fibrosis transmembrane conductance regulator (CFTR)-impaired endothelial cells (ECs) revealing a pro-inflammatory phenotype [1]. Indeed, CFTR impairment in different endothelial models and organisms, and in the absence of concomitant infection, suggests that ECs are an overlooked mediator in the exaggerated pro-inflammatory phenotype observed in cystic fibrosis (CF). Whether endothelial CFTR is involved in other vascular diseases is an intriguing question. Indeed, a recent report indicates a pivotal role of CFTR in pulmonary arterial hypertension (PAH) [2]. The role of endothelial CFTR dysfunction goes beyond cystic fibrosis by playing a role in pulmonary arterial hypertension <https://bit.ly/2UnC7IF>
Spatial mapping reveals human adipocyte subpopulations with distinct sensitivities to insulin
Authors: Jesper Bäckdahl, Lovisa Franzén, Lucas Massier, Qian Li, Jutta Jalkanen, Hui Gao, Alma Andersson, Nayanika Bhalla, Anders Thorell, Mikael Rydén, Patrik L. Ståhl, Niklas Mejhert
Journal: Cell Metabolism (2021)

The contribution of cellular heterogeneity and architecture to white adipose tissue (WAT) function is poorly understood. Herein, we combined spatially resolved transcriptional profiling with single-cell RNA sequencing and image analyses to map human WAT composition and structure. This identified 18 cell classes with unique propensities to form spatially organized homo- and heterotypic clusters. Of these, three constituted mature adipocytes that were similar in size, but distinct in their spatial arrangements and transcriptional profiles. Based on marker genes, we termed these AdipoLEP, AdipoPLIN, and AdipoSAA. We confirmed, in independent datasets, that their respective gene profiles associated differently with both adipocyte and whole-body insulin sensitivity. Corroborating our observations, insulin stimulation in vivo by hyperinsulinemic-euglycemic clamp showed that only AdipoPLIN displayed a transcriptional response to insulin. Altogether, by mining this multimodal resource we identify that human WAT is composed of three classes of mature adipocytes, only one of which is insulin responsive.
Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol
Authors: Louise Sigfrid, Thomas M. Drake, Ellen Pauley, Edwin C. Jesudason, Piero Olliaro, Wei Shen Lim, Annelies Gillesen, Colin Berry, David J. Lowe, Joanne McPeake, Nazir Lone, Daniel Munblit, Muge Cevik, Anna Casey, Peter Bannister, Clark D. Russell, Lynsey Goodwin, Antonia Ho, Lance Turtle, Margaret E. O'Hara, Claire Hastie, Chloe Donohue, Rebecca G. Spencer, Cara Donegan, Alison Gummery, Janet Harrison, Hayley E. Hardwick, Claire E. Hastie, Gail Carson, Laura Merson, J. Kenneth Baillie, Peter Openshaw, Ewen M. Harrison, Annemarie B. Docherty, Malcolm G. Semple, Janet T. Scott
Journal: The Lancet Regional Health - Europe (2021)
DOSE-DEPENDENT CONTRIBUTION OF HUMAN PERIPHERAL BLOOD CD34-POSITIVE CELL TRANSPLANTATION TO HEPATIC REGENERATION AFTER CCL4 CHRONIC LIVER INJURY
Authors: Hashimoto O, Taniguchi E, Ueno T, Sata M, Iwamoto H, Nakamura T, Tsutsumi, Torimura T, Naitou M
Journal: Hepatology (2010)
P-239 Consensus molecular subtypes of morphological regions on colorectal tumors
Authors: V. Popovici, T. Ivkovic, M. Hrivnakova, R. Nenutil, L. Zdražilová-Dubská, M. Nemecek, O. Slaby, B. Bencsiková, E. Budinska
Journal: Annals of Oncology (2021)
P-84 Genotype-fenotype correlation in patients with Lynch syndrome and colorectal cancer
Authors: J. Garcia-Cuesta, D. Viñal, M. Gomez-Barreda, A. Gallego, O. Higuera, L. Ruiz-Giménez, D. Sanchez, N. Rodríguez-Salas
Journal: Annals of Oncology (2021)
Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the Global Burden of Diseases Study 2015
Authors: Aaron J Cohen, Michael Brauer, Richard Burnett, H Ross Anderson, Joseph Frostad, Kara Estep, Kalpana Balakrishnan, Bert Brunekreef, Lalit Dandona, Rakhi Dandona, Valery Feigin, Greg Freedman, Bryan Hubbell, Amelia Jobling, Haidong Kan, Luke Knibbs, Yang Liu, Randall Martin, Lidia Morawska, C Arden Pope, Hwashin Shin, Kurt Straif, Gavin Shaddick, Matthew Thomas, Rita van Dingenen, Aaron van Donkelaar, Theo Vos, Christopher J L Murray, Mohammad H Forouzanfar
Journal: The Lancet Global Health (2017)
P-212 The genetic and epigenetic abnormalities of plasma cfDNA as liquid biopsy biomarkers for diagnosis and prognosis stratification of pancreatic ductal adenocarcinoma
Authors: Y. Wang, R. Jiang, S. Xiao, Y. Shi, J. Zheng, Z. Li, J. Peng, J. Sun, G. Yang, J. Yuan, W. Lou
Journal: Annals of Oncology (2021)
Pulmonary
Authors: U. Merz, Th. Peschgens, G. Kusenbach, M. Böhle, H. Hörnchen, L. Schrod, T. Neuhaus, R. Buhl, H. Pfüller, H. B. von Stockhausen, J. Ament, S. Nichani, D. Chang, S. Lee, J. Britto, K. Thomas, S. Nadel, P. Habibi, M. Levin, C. M. Owens, Ira M. Cheifetz, Jon N. Meliones, Barbara G. Wilson, Frank H. Kern, William J. Greeley, Eric G. Brouwer, Mark A. van der Hoeven, Danillo W. Gavilanes, Pieter L. Degraeuwe, Wiel J. Maertzdorf, Carlos E. Blanco, G. A. B. Russell, M. Baglaj, N. Marlow, H. R. Noblett, R. Spicer, P. J. Fleming, R. Nekvasil, G. Trittewein, V. Vasek, M. Fedora, Catherine Caronia, Peter Silver, Laura Nimkoff, Cari Quinn, Jack Gorvoy, Mayer Sagy
Journal: Intensive Care Medicine (1996)
Management of Patients With Microhematuria
Authors: Clark Judge, Adam S. Cifu, Sarah Faris
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups
Authors: Eileen M. Boyle, Adam Rosenthal, Hussein Ghamlouch, Yan Wang, Phillip Farmer, Michael Rutherford, Cody Ashby, Michael Bauer, Sarah K. Johnson, Christopher P. Wardell, Yubao Wang, Antje Hoering, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Bart Barlogie, Madhav V. Dhodapkar, Faith E. Davies, Gareth J. Morgan, Frits van Rhee, Brian A. Walker
Journal: Leukemia (2021)
Intent vs. impact: calling time on outdated phenotypic labels in dermatology
Authors: I.M. Winship, D Bajwa, N. Rajan
Journal: British Journal of Dermatology (2021)

Active social justice movements are exposing the structural disempowerment of minority groups throughout Western societies, including in healthcare. In the realm of rare genetic skin diseases, the term 'turban tumour' persists on PUBMED searches as recently as 2021 and is a pejorative and culturally insensitive description.
A Pharmacologic Approach Using Pomalidomide and Dexamethasone to Study Stage-Specific Regulation of Erythroid Progenitors
Authors: Brian M Dulmovits, Nan Wang, Hongxia Yan, Julien Papoin, Ryan Ashley, John Hale, Jeffrey M Lipton, Mohandas Narla, Anupama Narla, Lionel Blanc
Journal: Blood (2017)
Central Nervous System Relapse in Diffuse Large B Cell Lymphoma—Predictors at Diagnosis
Authors: Sabarish Ayyappan, Fahrettin Covut, Dhivya Prabhakar, Vinita Gupta, Ehsan Malek, Leland Metheny, Ben K. Tomlinson, Richard Creger, Brenda W. Cooper, Hillard M Lazarus, Marcos de Lima, Paolo Caimi
Journal: Blood (2017)
High-resolution Hi-C maps highlight multiscale 3D epigenome reprogramming during pancreatic cancer metastasis
Authors: Bo Ren, Jinshou Yang, Chengcheng Wang, Gang Yang, Huanyu Wang, Yuan Chen, Ruiyuan Xu, Xuning Fan, Lei You, Taiping Zhang, Yupei Zhao
Journal: Journal of Hematology & Oncology (2021)

Abstract Background Pancreatic cancer’s poor prognosis is caused by distal metastasis, which is associated with epigenetic changes. However, the role of the 3D epigenome in pancreatic cancer biology, especially its metastasis, remains unclear. Methods Here, we developed high-resolution 3D epigenomic maps of cells derived from normal pancreatic epithelium, primary and metastatic pancreatic cancer by in situ Hi-C, ChIP-seq, ATAC-seq, and RNA-seq to identify key genes involved in pancreatic cancer metastasis Results We found that A/B compartments, contact domains, and chromatin loops changed significantly in metastatic pancreatic cancer cells, which are associated with epigenetic state alterations. Moreover, we found that upregulated genes, which were located in switched compartments, changed contact domains, and metastasis-specific enhancer-promoter loops, were related to cancer metastasis and poor prognosis of patients with pancreatic cancer. We also found that transcription factors in specific enhancer-promoter loop formation were also associated with metastasis. Finally we demonstrated that LIPC, looped to metastasis-specific enhancers, could promote pancreatic cancer metastasis. Conclusions These results highlight the multiscale 3D epigenome reprogramming during pancreatic cancer metastasis and expand our knowledge of mechanisms of gene regulation during pancreatic cancer metastasis.
The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer
Authors: William A. Freed-Pastor, Laurens J. Lambert, Zackery A. Ely, Nimisha B. Pattada, Arjun Bhutkar, George Eng, Kim L. Mercer, Ana P. Garcia, Lin Lin, William M. Rideout, William L. Hwang, Jason M. Schenkel, Alex M. Jaeger, Roderick T. Bronson, Peter M.K. Westcott, Tyler D. Hether, Prajan Divakar, Jason W. Reeves, Vikram Deshpande, Toni Delorey, Devan Phillips, Omer H. Yilmaz, Aviv Regev, Tyler Jacks
Journal: Cancer Cell (2021)
Targeted temperature management following out-of-hospital cardiac arrest: a systematic review and network meta-analysis of temperature targets
Authors: Shannon M. Fernando, Pietro Di Santo, Behnam Sadeghirad, Jean-Baptiste Lascarrou, Bram Rochwerg, Rebecca Mathew, Mypinder S. Sekhon, Laveena Munshi, Eddy Fan, Daniel Brodie, Kathryn M. Rowan, Catherine L. Hough, Shelley L. McLeod, Christian Vaillancourt, Sheldon Cheskes, Niall D. Ferguson, Damon C. Scales, Claudio Sandroni, Jerry P. Nolan, Benjamin Hibbert
Journal: Intensive Care Medicine (2021)
Corrigendum to ’Decellularized disc hydrogels for hBMSC tissue-specific differentiation and tissue regeneration’ [Bioactive Materials 6 (2021) 3541–3556]
Authors: Yizhong Peng, Xiangcheng Qing, Hui Lin, Donghua Huang, Jinye Li, Shuo Tian, Sheng Liu, Xiao Lv, Kaige Ma, Rui Li, Zilong Rao, Ying Bai, Songfeng Chen, Ming Lei, Daping Quan, Zengwu Shao
Journal: Bioactive Materials (2021)

[This corrects the article DOI: 10.1016/j.bioactmat.2021.03.014.].
Removal of a huge biliary stone using a novel spiral basket via the endoscopic ultrasound-guided hepaticojejunostomy route
Authors: Takeshi Ogura, Jyunichi Kawai, Kyohei Nishiguchi, Yoshitaro Yamamoto, Kazuhide Higuchi
Journal: Endoscopy (2021)

Antegrade bile duct stone removal is an option for the treatment of bile duct stones with inaccessible papillae, for example due to surgically altered anatomy [1] [2] [3]. Acute pancreatitis can develop as a complication of this procedure because it requires endoscopic papillary balloon dilation. Alternatively, transluminal stone removal can be performed without the risk of acute pancreatitis [4]. However, during transluminal stone removal, stones can migrate into the right bile duct system or B2. Therefore, transluminal stone removal should be attempted using special stone-catching devices. Recently, a novel spiral basket catheter (VorticCatch V; Olympus Medical Systems, Tokyo, Japan) has become available in Japan ([Fig. 1]). The spiral shape of this device, along with the presence of a guidewire, enhances its ability to catch stones. We herein describe the technical procedure for removal of a huge common bile duct (CBD) stone via the endoscopic ultrasound (EUS)-guided hepaticojejunostomy (HJS) route using this novel spiral basket catheter.
Local recurrence in patients undergoing wide excision and sentinel lymph node biopsy for cutaneous malignant melanoma: A single-center, retrospective cohort analysis
Authors: Richard J. Straker, Nicholas Kelly, Cimarron E. Sharon, Adrienne B. Shannon, Xiaowei Xu, David E. Elder, Emily Y. Chu, John T. Miura, Giorgos C. Karakousis
Journal: Journal of the American Academy of Dermatology (2021)
Circulating Tumor DNA Analysis Detects <i>FGFR2</i> Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer
Authors: Tomoko Jogo, Yoshiaki Nakamura, Kohei Shitara, Hideaki Bando, Hisateru Yasui, Taito Esaki, Tetsuji Terazawa, Taroh Satoh, Eiji Shinozaki, Tomohiro Nishina, Yu Sunakawa, Yoshito Komatsu, Hiroki Hara, Eiji Oki, Nobuhisa Matsuhashi, Takashi Ohta, Takeshi Kato, Koushiro Ohtsubo, Takeshi Kawakami, Naohiro Okano, Yoshiyuki Yamamoto, Takanobu Yamada, Akihito Tsuji, Justin I. Odegaard, Hiroya Taniguchi, Toshihiko Doi, Satoshi Fujii, Takayuki Yoshino
Journal: Clinical Cancer Research (2021)

Abstract Purpose: FGFR2 amplification is associated with poor prognosis in advanced gastric cancer and its subclonal heterogeneity has been revealed. Here, we examined whether circulating tumor DNA (ctDNA) was useful for detecting FGFR2 amplification and co-occurring resistance mechanisms in advanced gastric cancer. Experimental Design: We assessed genomic characteristics of FGFR2-amplified advanced gastric cancer in a nationwide ctDNA screening study. We also analyzed FGFR2 amplification status in paired tissue and plasma samples with advanced gastric cancer. In addition, we examined patients with FGFR2-amplified advanced gastric cancer identified by ctDNA sequencing who received FGFR inhibitors. Results: FGFR2 amplification was more frequently detected by ctDNA sequencing in 28 (7.7%) of 365 patients with advanced gastric cancer than by tissue analysis alone (2.6%–4.4%). FGFR2 amplification profiling of paired tissue and plasma revealed that FGFR2 amplification was detectable only by ctDNA sequencing in 6 of 44 patients, which was associated with a worse prognosis. Two patients in whom FGFR2 amplification was detected by ctDNA sequencing after tumor progression following previous standard chemotherapies but not by pretreatment tissue analysis had tumor responses to FGFR inhibitors. A third patient with FGFR2 and MET co-amplification in ctDNA showed a limitation of benefit from FGFR inhibition, accompanied by a marked increase in the MET copy number. Conclusions: ctDNA sequencing identifies FGFR2 amplification missed by tissue testing in patients with advanced gastric cancer, and these patients may respond to FGFR inhibition. The utility of ctDNA sequencing warrants further evaluation to develop effective therapeutic strategies for patients with FGFR2-amplified advanced gastric cancer.